Patent ID: 7638523

Claim:
A method of treating a disease or condition in which c-kit receptor activity contributes to the pathology or symptomology of the disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure of Formula (1) or Formula (46), or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from asthma, allergic sinusitis, allergic rhinitis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, pulmonary fibrosis, liver fibrosis, scleroderma, irritable bowel syndrome, idiopathic pulmonary arterial hypertension and primary pulmonary hypertension, and wherein: Ar is selected from an optionally substituted five-membered aromatic heterocycle, an optionally substituted five-membered aromatic carbocycle, an optionally substituted six-membered aromatic heterocycle, and a substituted, optionally further substituted phenyl; Q is selected from the group consisting of or Q is selected from the group consisting of wherein: R A is selected from —NH 2 , —NEt 2 , and —NH(CH 2 ) n OH, and n is 1 to; R B is selected from the group consisting of —CH 2 OH, —CH 2 CH 2 OH, and —CH 2 CH 2 CH 2 OH; R C is at 2, 3, or 4 position of the piperidine ring; and R C is selected from the group consisting of —C(O)NHEt, —C(O)NEt 2 , c-butyl, c-pentyl, —C(O)NH— thiazole, oxazole, thiazole, —S(O) 2 NH 2 , —S(O) 2 NHEt, and —S(O) 2 NEt 2 ; each R D is independently selected from —(CH 2 ) k OH or —(CH 2 ) k CO 2 H, and k is 1 to 6; R E is at 2, 3, or 4 position of the piperidine ring; and R E is selected from the group consisting of —C(O)NH 2 , —C(O)NHEt, and —C(O)NEt 2 , and R F is thiazole, pyrazole, or isoxazole; each R 1 is independently selected from the group consisting of H, halogen, and an optionally substituted moiety selected from —L 1 -alkyl, —L 1 -cycloalkyl, —L 1 -heteroalkyl, —L 1 -haloalkyl, —L 1 -aryl, —L 1 -heterocycloalkyl, and —L 1 -heteroaryl; wherein L 1 is selected from a bond, —O—, —NH—, —S—, —C(O)—, —C(S)—, —C(O)O—, —C(O)NH—, —S(O)—, —S(O) 2 —, —C(O)NH(CR″ 2 ) 1-6 C(O)O—, —C(O)NR″NR″C(O)O—, and —S(O)NH—; each R″ is independently H, OH, halogen, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkyl, halo-C 1-6 alkoxy, aryl, haloaryl, or heteroaryl; or any two adjacent R 1 groups together may form an optionally substituted 5 to 8-membered heterocyclic, cycloalkyl, or aryl ring; and R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl and wherein, the compound is an inhibitor of c-kit receptor activity.